Jazz Pharmaceuticals plc 8-K, filed Jul 25, 2025
Jazz Pharmaceuticals plc (JAZZ)
8-K
2025-07-25
For: 2025-07-24
View Original
Added on
April 08, 2026
About this 8-K
Jazz Pharmaceuticals plc filed this 8-K on July 25, 2025, reporting on events of July 24, 2025.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File No.) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including zip code)
011-353 -1 -634-7800
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
Results of Matters Presented at the 2025 Annual General Meeting of Shareholders
On July 24, 2025, we held our 2025 annual general meeting of shareholders, or the Annual Meeting, at our corporate headquarters located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland. At the Annual Meeting, our shareholders voted on four proposals, each of which is described in more detail in our definitive proxy statement on Schedule 14A as filed with the SEC on June 6, 2025, or the Proxy Statement. The results of the matters presented at the Annual Meeting, based on the presence in person or by proxy of holders of 55,808,012 of the 60,511,021 ordinary shares entitled to vote, are described below.
Proposal 1
Proposal 1 was to elect by separate resolutions each of the four nominees for director named below to hold office until our 2028 annual general meeting of shareholders. Each of the four nominees for director was elected as follows:
| Director Nominees | For | Against | Abstain | Broker Non-Votes | ||||||||||||||||||||||
| Jennifer E. Cook | 49,838,761 | 1,472,373 | 31,182 | 4,465,696 | ||||||||||||||||||||||
| Patrick G. Enright | 49,122,808 | 2,186,963 | 32,545 | 4,465,696 | ||||||||||||||||||||||
| Seamus Mulligan | 49,488,355 | 1,821,942 | 32,019 | 4,465,696 | ||||||||||||||||||||||
| Norbert G. Riedel, Ph.D. | 46,521,583 | 4,787,903 | 32,830 | 4,465,696 | ||||||||||||||||||||||
Proposal 2
Proposal 2 was to ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as our independent auditors for the fiscal year ending December 31, 2025 and to authorize, in a binding vote, our board of directors, acting through the audit committee, to determine the auditors’ remuneration. This proposal was approved as follows:
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 54,773,976 | 996,901 | 37,135 | — | |||||||||||||||||
Proposal 3
Proposal 3 was to approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement. This proposal was approved as follows:
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 48,261,149 | 2,887,574 | 193,593 | 4,465,696 | |||||||||||||||||
Proposal 4
Proposal 4 was to grant our board of directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. This proposal was approved as follows:
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 53,607,244 | 2,159,201 | 41,567 | — | |||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY | ||||||||
| By: | /s/ Neena Patil | |||||||
| Name: | Neena Patil | |||||||
| Title: | Executive Vice President and Chief Legal Officer | |||||||
Date: July 25, 2025